Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...

Alcoholism and alcohol use disorder (AUD) are major public health and socioeconomic issues. However, a handful of ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

The company tested cebranopadol, a dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist, in a late-stage trial on patients who have undergone cosmetic ...

The FDA extended the action date by 3 months to allow more time to review supplemental information.

The kappa opioid receptor (KOR) and the endogenous peptide-ligand dynorphin have received significant attention due the involvement in mediating a variety of behavioral and neurophysiological ...